180 related articles for article (PubMed ID: 19793710)
1. Suboptimal responses to imatinib in chronic myelogenous leukemia: what are they and how do they affect treatment?
Allen-Bard S
Clin J Oncol Nurs; 2009 Oct; 13(5):537-42. PubMed ID: 19793710
[TBL] [Abstract][Full Text] [Related]
2. Treatment options for patients with chronic myeloid leukemia who are resistant to or unable to tolerate imatinib.
Stein B; Smith BD
Clin Ther; 2010 May; 32(5):804-20. PubMed ID: 20685492
[TBL] [Abstract][Full Text] [Related]
3. Dynamics of the emergence of dasatinib and nilotinib resistance in imatinib-resistant CML patients.
Gruber FX; Ernst T; Porkka K; Engh RA; Mikkola I; Maier J; Lange T; Hochhaus A
Leukemia; 2012 Jan; 26(1):172-7. PubMed ID: 21818112
[No Abstract] [Full Text] [Related]
4. Dasatinib and nilotinib in imatinib-resistant Philadelphia-positive chronic myelogenous leukemia: a 'head-to-head comparison'.
Rosti G; Castagnetti F; Gugliotta G; Palandri F; Martinelli G; Baccarani M
Leuk Lymphoma; 2010 Apr; 51(4):583-91. PubMed ID: 20302388
[TBL] [Abstract][Full Text] [Related]
5. What is imatinib-resistant chronic myeloid leukemia? Identifying and managing loss of response.
Zeidan A; Wang ES; Wetzler M
Clin Adv Hematol Oncol; 2008 Sep; 6(9):673-83. PubMed ID: 18827790
[TBL] [Abstract][Full Text] [Related]
6. Treatment of chronic myeloid leukemia following imatinib resistance: a nursing guide to second-line treatment options.
Bauer S; Romvari E
Clin J Oncol Nurs; 2009 Oct; 13(5):523-34. PubMed ID: 19793709
[TBL] [Abstract][Full Text] [Related]
7. Pharmacoeconomic benefits of dasatinib in the treatment of imatinib-resistant patients with chronic myelogenous leukemia.
Taylor MJ; Scuffham PA
Expert Rev Pharmacoecon Outcomes Res; 2009 Apr; 9(2):117-21. PubMed ID: 19402798
[TBL] [Abstract][Full Text] [Related]
8. Dasatinib: from treatment of imatinib-resistant or -intolerant patients with chronic myeloid leukemia to treatment of patients with newly diagnosed chronic phase chronic myeloid leukemia.
Abbott BL
Clin Ther; 2012 Feb; 34(2):272-81. PubMed ID: 22285209
[TBL] [Abstract][Full Text] [Related]
9. Important therapeutic targets in chronic myelogenous leukemia.
Kantarjian HM; Giles F; Quintás-Cardama A; Cortes J
Clin Cancer Res; 2007 Feb; 13(4):1089-97. PubMed ID: 17317816
[TBL] [Abstract][Full Text] [Related]
10. Treatment selection after imatinib resistance in chronic myeloid leukemia.
Jabbour E; Cortes J; Kantarjian H
Target Oncol; 2009 Jan; 4(1):3-10. PubMed ID: 19343297
[TBL] [Abstract][Full Text] [Related]
11. Clinical algorithms for the treatment of patients with chronic myeloid leukemia: the 2010 perspective.
Jabbour E; Fullmer A; Cortés JE; Kantarjian H
Clin Lymphoma Myeloma Leuk; 2010 Jun; 10 Suppl 1():S6-13. PubMed ID: 20529808
[TBL] [Abstract][Full Text] [Related]
12. Bosutinib: a review of its use in patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
Syed YY; McCormack PL; Plosker GL
BioDrugs; 2014 Feb; 28(1):107-20. PubMed ID: 24420842
[TBL] [Abstract][Full Text] [Related]
13. P-loop mutations and novel therapeutic approaches for imatinib failures in chronic myeloid leukemia.
Cang S; Liu D
J Hematol Oncol; 2008 Oct; 1():15. PubMed ID: 18828913
[TBL] [Abstract][Full Text] [Related]
14. [Nilotinib in patients with chronic myeloid leukemia without response to imatinib].
Báez-de la Fuente E; Arellano-Severiano B
Rev Med Inst Mex Seguro Soc; 2014; 52(3):330-3. PubMed ID: 24878095
[TBL] [Abstract][Full Text] [Related]
15. [Efficacy of dasatinib in treatment of imatinib-resistant BCR/ABL positive leukemia].
Zhu Y; Pan LQ; Qian SX; Song P; Yu H; Zhang SJ; Ge Z; Hong M; Tian T; Li JY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Jun; 21(3):581-6. PubMed ID: 23815902
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and tolerance of dasatinib after imatinib failure or intolerance for patients with chronic myeloid leukemia treated in three different hospitals compare well with results achievable in formal clinical trials.
Zackova D; Klamova H; Muzik J; Cmunt E; Racil Z; Machova Polakova K; Dvorakova D; Jurcek T; Razga F; Cetkovsky P; Dusek L; Mayer J
Leuk Lymphoma; 2013 Oct; 54(10):2310-3. PubMed ID: 23373966
[No Abstract] [Full Text] [Related]
17. Combining nilotinib and imatinib improves the outcome of imatinib-resistant blast phase CML.
Zhu GR; Ji O; Ji JM; Zhang YC; Wu Y; Yu H; Jiang PJ; Shen Q
Acta Haematol; 2012; 127(3):152-5. PubMed ID: 22286512
[TBL] [Abstract][Full Text] [Related]
18. Polo-like kinase 1 (Plk1) as a novel drug target in chronic myeloid leukemia: overriding imatinib resistance with the Plk1 inhibitor BI 2536.
Gleixner KV; Ferenc V; Peter B; Gruze A; Meyer RA; Hadzijusufovic E; Cerny-Reiterer S; Mayerhofer M; Pickl WF; Sillaber C; Valent P
Cancer Res; 2010 Feb; 70(4):1513-23. PubMed ID: 20145140
[TBL] [Abstract][Full Text] [Related]
19. Delayed initiation of front-line imatinib therapy predicts for poor response to nilotinib as second-line treatment of imatinib-resistant or intolerant CML: single center report of the ENACT trial in Lebanon.
Otrock ZK; Mahfouz RA; Fahed Z; Farhat FS; Ziade A; Nasr F; Kassem N; Abboud MR
Int J Hematol; 2012 Oct; 96(4):521-4. PubMed ID: 22961257
[No Abstract] [Full Text] [Related]
20. How to monitor patients with chronic myelogenous leukemia.
O'Dwyer ME
J Natl Compr Canc Netw; 2003 Oct; 1(4):513-7. PubMed ID: 19774742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
